Cochrane · systematic review · CD012557
Baclofen for alcohol use disorder
Agabio, R, Saulle, R, Rösner, S, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
14
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 7 · 50%Low 0 · 0%Moderate 3 · 21.4%High 4 · 28.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlySummary of findings table ‐ Baclofen compared to placebo for alcohol use disorder
Population: alcohol use disorder
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Relapse: return to any drinking at end of treatment Summary of findings table ‐ Baclofen vs placebo | RR 0.87 [0.77, 0.99] | 12 studies · 1057 participants | Moderate Downgraded: inconsistency |
Frequency of use: % days abstinence at end of treatment Summary of findings table ‐ Baclofen vs placebo | no estimate extracted | 16 studies · 1273 participants | High |
Frequency of use: heavy drinking days at end of treatment Summary of findings table ‐ Baclofen vs placebo | no estimate extracted | 13 studies · 840 participants | Moderate Downgraded: inconsistency |
Amount of use: drink per drinking days at end of treatment Summary of findings table ‐ Baclofen vs placebo | no estimate extracted | 9 studies · 392 participants | Moderate Downgraded: risk of bias, imprecision |
Adverse events: number of participants with ≥ 1 adverse event at end of treatment Summary of findings table ‐ Baclofen vs placebo | RR 1.05 [0.99, 1.11] | 10 studies · 738 participants | High |
Dropouts at end of treatment Summary of findings table ‐ Baclofen vs placebo | RR 0.88 [0.74, 1.03] | 17 studies · 1563 participants | High |
Dropouts due to adverse events Summary of findings table ‐ Baclofen vs placebo | RR 1.39 [0.89, 2.18] | 16 studies · 1499 participants | High |
Summary of findings table ‐ Baclofen compared to acamprosate for alcohol use disorder
Population: alcohol use disorder
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Relapse: return to any drinking at end of treatment Summary of findings table ‐ Baclofen vs acamprosate | RR 1.25 [0.71, 2.2] | 1 study · 60 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events: number of participants with at least one adverse event at end of treatment Summary of findings table ‐ Baclofen vs acamprosate | RR 0.63 [0.23, 1.69] | 1 study · 60 participants | Very low Downgraded: risk of bias, imprecision |
Dropouts at end of treatment Summary of findings table ‐ Baclofen vs acamprosate | RR 0.56 [0.21, 1.46] | 1 study · 60 participants | Very low Downgraded: risk of bias, imprecision |
Dropouts due to adverse events Summary of findings table ‐ Baclofen vs acamprosate | RR 0.33 [0.01, 7.87] | 1 study · 60 participants | Very low Downgraded: risk of bias, imprecision |
Summary of findings table ‐ Baclofen compared to naltrexone for alcohol use disorder
Population: alcohol use disorder
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Relapse: return to any drinking at end of treatment Summary of findings table ‐ Baclofen vs naltrexone | RR 2.5 [1.12, 5.56] | 1 study · 60 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events: number of participants with ≥ 1 adverse event at end of treatment Summary of findings table ‐ Baclofen vs naltrexone | RR 0.35 [0.15, 0.8] | 2 studies · 80 participants | Very low Downgraded: risk of bias, imprecision |
Dropouts at end of treatment Summary of findings table ‐ Baclofen vs naltrexone | RR 1 [0.32, 3.1] | 1 study · 60 participants | Very low Downgraded: risk of bias, imprecision |
Baclofen compared to placebo for alcohol use disorder
Population: adults (18 years and older) with alcohol use disorder
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Relapse return to any drinking at the end of treatment Baclofen vs placebo | RR 0.88 [0.74, 1.04] | 5 studies · 781 participants | Moderate Downgraded: inconsistency |
Frequency of use % days abstinence at the end of treatment Baclofen vs placebo | no estimate extracted | 6 studies · 465 participants | Low Downgraded: inconsistency |
Frequency of use % of heavy drinking days at the end of treatment Baclofen vs placebo | no estimate extracted | 3 studies · 186 participants | Moderate Downgraded: imprecision |
Amount of use drink per drinking days at the end of treatment Baclofen vs placebo | no estimate extracted | 2 studies · 72 participants | Low Downgraded: imprecision |
Adverse events number of participants with at least one side effect at the end of treatment Baclofen vs placebo | RR 1.04 [0.99, 1.1] | 4 studies · 430 participants | High |
Dropout at end of treatment Baclofen vs placebo | RR 0.98 [0.77, 1.26] | 8 studies · 977 participants | High |
Dropout due to adverse events Baclofen vs placebo | RR 1.11 [0.59, 2.07] | 7 studies · 913 participants | High |